1. Generics Bulletin
  2. >>Business
  3. >>Deals

Amneal Takes Control Of Kashiv Specialty In $100m+ Deal

Points To Value Of 505(b)(2) Pipeline And Complex Generics Experience

 
• By Dave Wallace

Amneal will take a majority stake in Kashiv Specialty Pharmaceuticals after striking a deal worth potentially more than $100m for a 98% stake in the hybrid 505(b)(2) and complex generics specialist.

Handshake
Amneal has agreed a deal to take a 98% stake in Kashiv Specialty • Source: Shutterstock

Amneal Pharmaceuticals is to take control of hybrid 505(b)(2) and complex generics specialist Kashiv Specialty Pharmaceuticals, after striking a deal that could be worth more than $100m for a 98% stakeholding.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business